ABBV-154 Clinical Trial
Official title:
A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154
This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.
n/a